

## DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

X	Original	Supplemental	Substitute
---	----------	--------------	------------

**As a below-named inventor, I hereby declare that:**

My residence, citizenship and mailing address are given below under my name.

I/We believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

# USE OF SUCCINIC ACID DERIVATIVES TO OBTAIN A MEDICINE FOR TREATING INFLAMMATION

the application for which

is attached hereto.

was filed on \_\_\_\_\_ as United States

Application Serial No.

and was amended on \_\_\_\_\_ (if applicable)

**X** was filed on 09 May 2000 as PCT International

Application No.

PCT/FR00/01246

and was amended on \_\_\_\_\_ (if applicable)

I/We have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above.

I/We acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in Section 1.56 of Title 37 of the Code of Federal Regulations, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I/We hereby claim foreign priority benefit under Section 119 (a) - (d) of Title 35 of the United States Code of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States identified below and also identify below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States filed by me on the same subject matter and having a filing date before that of the application(s) from which priority is claimed:

Country	Number	Filing Date	Priority Claimed	
			Yes	No
FR	99/05978	11 May 1999	X	

I/We hereby claim benefit under Section 119(e) of Title 35 of the United States Code of any United States provisional application(s) identified below:

Application No.

Filing Date

I/We hereby claim benefit under Section 120 of Title 35 of the United States Code of any United States application(s) or PCT international application(s) designating the United States identified below:

Application Serial No.

Filing Date

Status

I/We hereby appoint Michael D. Alexander, Reg. No. 36,080; and Paul E. Dupont, Reg. No. 27,438, or any of them my/our attorneys or agents with full power of substitution and revocation to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO:

DIRECT TELEPHONE CALLS TO:

Patent Department  
Sanofi-Synthelabo Inc.  
9 Great Valley Parkway  
P.O. Box 3026  
Malvern, PA 19355

MICHAEL D. ALEXANDER

Telephone No. 610-889-8802

I/We hereby declare that all statements made herein and in the above-identified application of my/our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole inventor Dominique CAILLE

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_

Mailing Address/Residence 14, sentier des Essarts, F-92190 Meudon, France

Citizenship France

U / U 30752

531 Rec'd PCT/FT 07 NOV 2001

Application of: Dominique CAILLE

Docket No.: SYL 550

Filing Under 35 U.S.C. § 371

Filed As a U.S. National Phase Application of  
International Application No. PCT/FR00/01246  
Filed 09 May 2000


FOR: USE OF SUCCINIC ACID DERIVATIVES TO OBTAIN A  
MEDICINE FOR TREATING INFLAMMATION

**CERTIFICATE UNDER 37 C.F.R. 1.10**

Express Mail Label No.: EL676470703US

Date of Deposit: November 7, 2001

I hereby certify that this paper is being deposited with the United States  
Postal Service "Express Mail Post Office to Addressee" Service on the  
date indicated above, and is addressed to:  
Commissioner for Patents, Box PCT, Attn: EO/US, Washington, DC  
20231

  
Signature